Saudi Arabia Point of Care Diagnostics Market Overview, 2031

Key Insights

• According to the research report, "Saudi Arabia Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the Saudi Arabia Point of Care Diagnostics Market is expected to reach a market size of more than 841 Million by 2031.
• The Point-of-Care (POC) diagnostics market in Saudi Arabia is undergoing rapid expansion, driven primarily by the high burden of non-communicable cardiometabolic conditions (particularly Type 2 diabetes, obesity, and cardiovascular disorders) alongside the sweeping digital healthcare transformation under Saudi Vision 2030. A major technological breakthrough in the Kingdom is the widespread integration of automated microfluidic multiplex PCR platforms and cloud-connected, benchtop immunoassay instruments.
• Sustained adoption of point-of-care testing across Saudi Arabia is supported by concrete epidemiological indicators and institutional procurement patterns. Institutional care facilities (hospitals, outpatient polyclinics, and specialist medical centers) account for over 50% of total POC device procurement across the Kingdom. Furthermore, driven by state health programs monitoring chronic conditions, handheld blood-glucose meters and lipid profile strips comprise the largest volume product category in the home-testing and self-monitoring market segment.
• As the Ministry of Health delegates operational management to regional Health Clusters, public health strategy is shifting away from tertiary care toward localized primary care and preventive health networks. This structural pivot creates strong momentum for multi-parametric benchtop analyzers, permitting primary care physicians to run routine HbA1c, liver function, and renal panels on-site during consultations, directly improving chronic disease compliance and reducing avoidable emergency room visits.

Market Outlook

• Health authorities are encouraging the adoption of Bluetooth- and Wi-Fi-enabled home testing kits that automatically transmit continuous glucose readings, coagulation monitors, and lateral flow immunoassay results into unified patient health records. This digital integration combined with a growing consumer appetite for over-the-counter wellness, fertility, and respiratory self-test kits is fostering a robust out-of-hospital POC marketplace across the Kingdom.
• Prominent international suppliers active in Saudi Arabia's point-of-care diagnostics sector include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation (Cepheid), Siemens Healthineers, bioMérieux, BD (Becton, Dickinson and Company), and QIAGEN, operating under medical device registration, technical evaluation, and clearance frameworks administered by the Saudi Food and Drug Authority (SFDA) in coordination with policy guidelines set by the Ministry of Health (MOH) and the Public Health Authority (Weqaya).

Market Dynamics

Driver: Vision 2030 healthcare modernization and chronic disease burden
Driven by Saudi Arabia's Vision 2030 initiative, the national healthcare sector is undergoing extensive structural transformation and substantial infrastructure investments. This macro-shift, combined with a high local prevalence of chronic conditions (such as diabetes) and recurring acute care demands, fuels a massive, continuous requirement for decentralized point-of-care (POC) testing to optimize clinical workflows and patient outcomes.
Challenge: Rigorous SFDA dossier scrutiny and extended review timelines
Bringing advanced diagnostic technologies to market requires navigating meticulous regulatory evaluations managed by the Saudi Food and Drug Authority (SFDA). Stringent technical validation rules, comprehensive documentation requirements, and detailed review phases can introduce time-to-market delays and high administrative overhead for international device manufacturers.
Trend: Integration of artificial intelligence and expansion of remote care
The Saudi market is increasingly adopting smart, digitally connected POC devices integrated with AI-driven analytics and telemedicine platforms. These systems allow decentralized test data from remote clinics, mobile units, or home-care environments to sync seamlessly with centralized health networks for efficient tracking and precision care.

Segment Analysis

Saudi Arabia Point of Care Diagnostics By Product
• Glucose monitoring kits in Saudi Arabia are increasingly becoming part of connected diabetes-management ecosystems rather than functioning only as standalone meters. Product differentiation is shifting toward small-volume sampling, easier strip handling, automatic storage of readings, connectivity with digital health platforms, and integration with longer-term glucose-management workflows. The SFDA explicitly classifies blood-glucose meters and strips as IVD medical devices, while its regulatory framework also covers accessories such as lancets when supplied as part of a glucose-monitoring kit.
• Infectious-disease POC kits in Saudi Arabia span simple rapid assays through molecular platforms capable of pathogen-specific detection. Their distinctive value is bringing diagnostic information closer to the clinical decision rather than relying exclusively on centralized laboratory workflows. Saudi Arabia's IVD classification gives particular regulatory attention to infectious-disease applications, including tests for transmissible agents, life-threatening diseases, infectious-disease monitoring, and conditions where an erroneous result could have serious consequences.
• Pregnancy and fertility testing kits are naturally suited to decentralized use because urine-based testing can be performed privately with minimal equipment. Saudi Arabia's IVD classification specifically identifies pregnancy and fertility testing within the self-testing category, creating a clear regulatory pathway for consumer-oriented products. This encourages differentiation around simple sample collection, intuitive result interpretation, compact packaging, and designs that reduce user errors.
• Hematology POC kits bring selected blood measurements closer to the patient through portable analyzers, cartridges, and simplified specimen workflows. Their applications can extend from hemoglobin-related measurements to coagulation and other blood parameters used in acute or procedural settings. Saudi Arabia's POC regulatory environment is notable because the SFDA has issued dedicated guidance for POC medical-device manufacturing within healthcare facilities, including in-house IVD development.
• Cardiometabolic monitoring kits in Saudi Arabia are increasingly moving toward integrated management of glucose, HbA1c, cholesterol, ketones, and other related biomarkers. The country's broader digital-health direction is also encouraging connected monitoring rather than isolated measurements; the Ministry of Health has described a national diabetes-monitoring initiative based on electronic and proactive tracking of diabetes-related indicators. This creates a product environment in which meters, consumables, connectivity, software, and clinical data exchange can form one ecosystem.
• Urinalysis testing kits are well suited to decentralized testing because urine collection is non-invasive and multi-parameter strips require little instrumentation. Saudi Arabia's IVD classification specifically identifies products used to detect glucose, erythrocytes, leucocytes, and bacteria in urine within its self-testing classification, highlighting the regulatory recognition of strip-based urine diagnostics.
• Cholesterol test strips connect conventional lipid testing with near-patient cardiometabolic screening through compact readers and small blood specimens. Saudi Arabia's IVD rules explicitly identify cholesterol-level detection among self-testing applications, making cholesterol testing one of the diagnostic categories with a clearly recognized decentralized use case. Product differentiation therefore increasingly centers on simplified capillary sampling, rapid processing, integrated lipid measurements, and digital storage or transmission of results.
• Other Products include cardiac biomarkers, inflammatory markers, electrolytes, blood gases, coagulation assays, toxicology, reproductive biomarkers, and multi-analyte platforms. Saudi Arabia's regulatory framework is broad enough to accommodate sophisticated IVD systems and emerging diagnostic applications, including companion diagnostics and in-house IVD development. The SFDA's regulatory direction also explicitly emphasizes innovation, post-market surveillance, analytical and clinical performance, and lifecycle oversight.



Saudi Arabia Point of Care Diagnostics By Technology/Platform
• Lateral flow assays remain important for decentralized diagnostics in Saudi Arabia because they combine portability, rapid operation, simple specimen handling, and limited equipment requirements. They are particularly compatible with infectious-disease screening, pregnancy testing, fertility testing, and other rapid applications. The SFDA's classification framework distinguishes self-testing applications such as pregnancy, fertility, cholesterol, and selected urine tests, while infectious-disease applications can fall into higher-risk categories depending on their intended purpose.
• PCR and isothermal nucleic-acid amplification technologies are bringing molecular diagnostics closer to patients through compact analyzers and integrated cartridges. These platforms can combine specimen preparation, amplification, detection, and interpretation within a controlled workflow, reducing manual laboratory steps. Saudi Arabia's IVD classification gives special consideration to infectious agents, life-threatening diseases, sexually transmitted agents, and situations where erroneous results could lead to serious patient-management consequences.
• Microfluidics and immunoassays compress laboratory processes into cartridges and compact analyzers, enabling small-volume specimens to be processed close to the patient. Potential applications span reproductive biomarkers, infectious-disease antigens and antibodies, cardiac markers, endocrine measurements, and cardiometabolic testing. Saudi Arabia's regulatory framework covers a broad range of IVD purposes and has also developed dedicated guidance for advanced and innovative medical-device technologies.
• Dipsticks and test strips remain among the most accessible POC technologies in Saudi Arabia because they require minimal instrumentation and can support testing directly at or near the patient. The SFDA explicitly recognizes glucose, urine analytes, pregnancy, fertility, and cholesterol applications within its IVD classification framework, giving strip-based products a broad range of potential decentralized uses.

Saudi Arabia Point of Care Diagnostics By End-User
• Hospitals and critical-care centers are important environments for Saudi POC diagnostics because rapid testing can support immediate clinical decisions in emergency, intensive-care, surgical, and other high-acuity settings. The SFDA has dedicated guidance covering POC medical-device manufacturing and in-house IVDs within healthcare facilities, including requirements around documentation, staff qualifications, design validation, and safety. This regulatory structure reinforces the concept of POC testing as a controlled clinical process rather than simply the placement of a handheld analyzer beside a patient.
• Clinical and diagnostic laboratories increasingly function as the quality-management backbone for decentralized testing in Saudi Arabia. Their role can include method verification, quality control, calibration, operator training, troubleshooting, review of unexpected results, and confirmation testing where appropriate. This complements the SFDA's broader lifecycle approach, which covers technical documentation, clinical evaluation, marketing authorization, post-market surveillance, adverse-event monitoring, and safe use of medical devices and IVDs.
• Home care and self-testing represent the consumer-facing side of Saudi Arabia's POC diagnostics ecosystem, particularly for glucose, pregnancy, fertility, cholesterol, and selected urine-based applications. The SFDA's IVD classification explicitly identifies pregnancy, fertility, cholesterol, glucose, and selected urine analytes within self-testing, giving these categories a defined regulatory context. Connected meters and digital-health platforms can further transform individual home readings into longitudinal records that support remote monitoring.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Point of Care Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Glucose Monitoring Kits
• Infectious Diseases Testing Kits
• Pregnancy And Fertility Testing Kits
• Hematology Testing Kits
• Cardiometabolic Monitoring Kits
• Urinalysis Testing Kits
• Cholesterol Test Strips
• Other Products

By Technology/Platform
• Lateral Flow Assays
• Molecular Diagnostics (PCR/INAAT)
• Microfluidics & Immunoassays
• Dipsticks & Test Strips

By End-User
• Hospitals & Critical Care Centers
• Clinical & Diagnostic Laboratories
• Home Care & Self-Testing

By Mode Of Purchase
• Prescription Based Products
• OTC Products

By Sample
• Blood
• Urine
• Nasal and Oropharyngeal Swabs